We are live on ! Find out more
TECH icon

Bio-Techne

528 hedge funds and large institutions have $12.3B invested in Bio-Techne in 2023 Q2 according to their latest regulatory filings, with 52 funds opening new positions, 206 increasing their positions, 189 reducing their positions, and 69 closing their positions.

New
Increased
Maintained
Reduced
Closed

151% more call options, than puts

Call options by funds: $20.8M | Put options by funds: $8.3M

80% more funds holding in top 10

Funds holding in top 10: 59 (+4)

12% more capital invested

Capital invested by funds: $11.1B → $12.3B (+$1.28B)

1.25% more ownership

Funds ownership: 94.76%96.01% (+1.3%)

9% more repeat investments, than reductions

Existing positions increased: 206 | Existing positions reduced: 189

4% less funds holding

Funds holding: 549528 (-21)

25% less first-time investments, than exits

New positions opened: 52 | Existing positions closed: 69

Holders
528
Holders Change
-21
Holders Change %
-3.83%
% of All Funds
8.29%
Holding in Top 10
9
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+80%
% of All Funds
0.14%
New
52
Increased
206
Reduced
189
Closed
69
Calls
$20.8M
Puts
$8.3M
Net Calls
+$12.5M
Net Calls Change
+$3.23M
Name Holding Trade Value Shares
Change
Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$1.5B -$6.02M -74,938 -0.4%
BlackRock
2
BlackRock
New York
$1.38B +$74.1M +922,301 +6%
State Street
3
State Street
Massachusetts
$524M +$10.9M +136,127 +2%
BAMCO Inc
4
BAMCO Inc
New York
$439M +$78.9K +982 +0%
Select Equity Group
5
Select Equity Group
New York
$368M -$90.6M -1,126,819 -20%
T. Rowe Price Associates
6
T. Rowe Price Associates
Maryland
$332M +$286M +3,559,781 +701%
Neuberger Berman Group
7
Neuberger Berman Group
New York
$308M -$21.9M -272,855 -7%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$289M -$15.8M -196,440 -5%
DDC
9
DF Dent & Co
Maryland
$267M +$26.3M +326,573 +11%
Ameriprise
10
Ameriprise
Minnesota
$259M +$10.6M +132,006 +4%
Morgan Stanley
11
Morgan Stanley
New York
$258M -$1.77M -22,072 -0.7%
BCM
12
Brown Capital Management
Maryland
$258M -$8.16M -101,485 -3%
MPI
13
Mairs & Power Inc
Minnesota
$250M +$2.71M +33,660 +1%
Wellington Management Group
14
Wellington Management Group
Massachusetts
$208M -$42.3M -526,827 -17%
William Blair Investment Management
15
William Blair Investment Management
Illinois
$189M +$186M +2,314,458 New
OCBV
16
Ownership Capital B.V.
Netherlands
$186M -$3.4M -42,254 -2%
Bank of New York Mellon
17
Bank of New York Mellon
New York
$178M -$8.17M -101,581 -4%
CIP
18
Champlain Investment Partners
Vermont
$174M +$19.3M +239,875 +13%
Macquarie Group
19
Macquarie Group
Australia
$173M +$13.2M +164,437 +8%
Mackenzie Financial
20
Mackenzie Financial
Ontario, Canada
$173M +$22M +274,048 +15%
Fidelity Investments
21
Fidelity Investments
Massachusetts
$148M -$363K -4,519 -0.2%
Norges Bank
22
Norges Bank
Norway
$147M +$5.74M +71,380 +4%
Invesco
23
Invesco
Georgia
$134M -$31.2M -387,532 -19%
Northern Trust
24
Northern Trust
Illinois
$130M -$1.52M -18,871 -1%
American Century Companies
25
American Century Companies
Missouri
$120M +$10.8M +134,127 +10%

TECH Hedge Fund Activity: Q2 2023 in Review

528 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Bio-Techne (TECH) for Q2 2023, worth a combined $12.3B — up 12% from $11.1B a quarter earlier.

Sellers outnumbered buyers: 69 funds closed out of TECH and 52 opened new positions — a net loss of 17 holders — while 189 trimmed existing stakes and 206 added.

The largest buyer was T. Rowe Price Associates, adding an estimated $286M. The largest seller was Select Equity Group, cutting an estimated $90.6M.

  • 528 institutional investors held Bio-Techne (TECH) as of Q2 2023, down from 549 in Q1 2023.
  • Funds reported $12.3B of Bio-Techne stock for Q2 2023, up 12% quarter-over-quarter.
  • 52 funds opened new Bio-Techne positions in Q2 2023 and 69 closed out, a net change of -17 holders.
  • The largest Bio-Techne buyer in Q2 2023 was T. Rowe Price Associates, an estimated $286M added.
  • The largest Bio-Techne seller in Q2 2023 was Select Equity Group, an estimated $90.6M sold.

Based on aggregated 13F filings for Q2 2023.